

## Change of Address

---

**June 26, 2017**

In accordance with Listing Rule 3.14, the Company advises that the **Registered Office & Principal Place of Business** will change effective immediately.

The new address is detailed below:

<b>Registered Office &amp; Principal Place of Business</b>
Level 3 62 Lygon Street Carlton Vic 3053 Australia  Phone: +61 (0) 3 9824 5254  <b>Postal address:</b> P.O. Box 655 Carlton South Vic 053

The office is staffed during normal business hour (Monday to Friday) from 08.30 to 17.00 AEST.



Phillip Hains  
Company Secretary

### **About Imugene (ASX:IMU)**

Imugene (ASX:IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. Developed by leading scientists at the Medical University of Vienna in Austria, the peptide vaccine is constructed from several B cell epitopes of HER-2/neu. It has been shown in pre-clinical studies and in one Phase I study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.

Imugene in partnership with the Medical University of Vienna is working to discover and develop mimotope-based immunotherapies against validated and new oncology targets. This partnership has the potential to create game-changing B Cell peptide vaccines that would replace or augment conventional monoclonal antibody therapies.

For further information please visit [www.imugene.com](http://www.imugene.com)

Sign up to follow @ TeamImugene on Twitter at <http://www.twitter.com/TeamImugene>. To follow Imugene on Facebook visit [www.facebook.com/imugene](http://www.facebook.com/imugene)